Equities research analysts forecast that NewLink Genetics Corp (NASDAQ:NLNK) will post $2.72 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for NewLink Genetics’ earnings. The highest sales estimate is $5.00 million and the lowest is $300,000.00. NewLink Genetics posted sales of $12.70 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 78.6%. The company is scheduled to issue its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that NewLink Genetics will report full-year sales of $2.72 million for the current year, with estimates ranging from $18.61 million to $23.60 million. For the next year, analysts expect that the company will post sales of $12.20 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow NewLink Genetics.
A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Tuesday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics in a report on Thursday, November 2nd. BidaskClub raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Stifel Nicolaus lifted their price objective on shares of NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Finally, Jefferies Group dropped their price objective on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating for the company in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $23.29.
Institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC bought a new stake in NewLink Genetics in the third quarter worth $4,581,000. Northern Trust Corp lifted its stake in NewLink Genetics by 4.0% in the second quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock worth $2,195,000 after purchasing an additional 11,532 shares during the last quarter. Neuberger Berman Group LLC bought a new stake in NewLink Genetics in the third quarter worth $305,000. Tudor Investment Corp ET AL bought a new stake in NewLink Genetics in the second quarter worth $286,000. Finally, Stifel Financial Corp bought a new stake in NewLink Genetics in the third quarter worth $402,000. 52.68% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “NewLink Genetics Corp (NLNK) Expected to Announce Quarterly Sales of $2.72 Million” was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/09/newlink-genetics-corp-nlnk-expected-to-announce-quarterly-sales-of-2-72-million.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.